Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi-Aventis 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Sanofi-Aventis 1Q11

Lantus sales were up 13% to $1.3 billion in the quarter.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis 1Q11

1Q Revenues: $9.3 billion (-2%)

1Q Earnings: $1.7 billion (-26%)

Comments: Lantus sales were up 13% to $1.3 billion in the quarter. Lovenox sales were down 27% to $821.9 million; Taxotere sales were down 32% to $538.5 million; and Plavix sales were down 14% to $682.3 million, due to generic competition, as well as austerity measures in EU and healthcare reform in the U.S. Eloxatin sales were up 173% to $265.0 million and Multaq sales were up 154% to $88.8 million. Results include a non-recurring charge of $458.2 million related to Merial assets. Revenues were also impacted by declining A/H1N1 sales compared to 1Q10.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters